Home » Newsletters » BioWorld Science

BioWorld Science

July 17, 2012

View Archived Issues

Scientists at Roche disclose new HDL cholesterol-raising agents

Reata Pharmaceuticals presents new inhibitors of NO production

Nerviano Medical Sciences prepares new protein kinase inhibitors

French scientists patent novel agents for AIDS

EVP-0015962 reduces total Abeta load

Swiss researchers patent novel anti-SOD1 antibodies

ST-101 triggers acetylcholine release via the Ca(V)3.1 channel

Ampio's anticancer candidate advances to preclinical development

Verastem provides update on pipeline projects

FDA accepts NDA for single-entity hydrocodone product

ASKP-1240 well tolerated in de novo kidney transplant recipients

St. Jude to study replacement therapy compounds from Retrophin

Phase I trial of bavituximab in rectal cancer commences

Encouraging results reported from phase I trial of ALN-TTR02

NuPathe resubmits migraine patch NDA

Novavax to provide VLP vaccine technology for public-private malaria partnership in India

GSK to acquire Human Genome Sciences

Anthera provides final data from PEARL-SC study

FDA approves drug to reduce risk of HIV infection

Biotest begins clinical study of BT-062 as part of combination therapy

Janssen R&D Ireland presents new antiviral agents

Clovis Oncology and Array BioPharma enter collaboration

Repros receives FDA guidance regarding phase II study in endometriosis

Lee's Pharmaceuticals licenses thymosin beta4 candidates in China and Taiwan

EW-7197 as a new therapeutic option for breast cancer metastasis

EMA accepts laquinimod MAA for relapsing-remitting multiple sclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...